<DOC>
	<DOC>NCT02757066</DOC>
	<brief_summary>The purpose of this study is to verify the efficacy of NPC-15 (melatonin 1 mg/d or 4 mg/d) versus placebo to sleep latency with electronic sleep diaries.</brief_summary>
	<brief_title>Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders</brief_title>
	<detailed_description>This study will be a multicenter, double-blind, randomized, placebo-controlled parallel group trial. The trial has five phases; the pre-screening phase, the screening phase, double-blinded treatment phase, open label treatment phase and post-treatment phase. The screening phase comprises a screening visit where subject's initial eligibility will be evaluated. During double-blinded treatment phase, patients who meet all entry criteria for the trial will be randomized into three groups, and they will be assigned NPC-15 1 mg, 4 mg or placebo before going to bed for 2 weeks. During open label treatment phase, all patients will be administered NPC-15 1 mg, 2 mg or 4 mg on the basis of their doctors' judgements.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders, Pervasive</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Female or male patients aged 6 to 15 years. Patients with "autism spectrum disorder" diagnosed by using DSM5. Patients with average of daily sleep latency persisted over 30 min and the condition is continuous over 3 months Patients who are outpatient, not hospitalized patient. Signed informed consent obtained from rearer(s)/parent(s)/guardian(s) of the patient, or signed IC or informed assent obtained from the patient themselves. Patients with at least severity in either Conceptual area, or Social area, or Practical area of intellectual disability have judged more than "severe" by using DSM5. Patients who took melatonin (including supplement) in history. Patients who had taken Ramelteon within 4 weeks before clinical study starts.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>NPC-15</keyword>
	<keyword>Sleep disorders</keyword>
	<keyword>Autism spectrum disorders</keyword>
	<keyword>DSM-5</keyword>
</DOC>